Heart Conditions — Expert Guides

Clot-Busting Drugs: When a Heart Attack Is Hours From Help

August 1, 2026

heart attack fibrinolysis clot-busting drugs

Key Points

A heart attack happens when a clot blocks an artery supplying the heart. Whatever else follows, that artery has to be opened, and quickly.
In a large hospital this is done with a thin tube passed up to the heart, then a balloon and a stent. In a hospital without that facility, the first step is a drug given into a vein that dissolves the clot.
The drug is not a second-rate substitute. When the specialist hospital is more than about two hours away, it opens the artery sooner than the journey would, and sooner is what counts.
The main risk is bleeding, including bleeding into the brain. It is uncommon, but it is the reason your medical team runs through a careful list of questions before giving it.
Almost everyone who receives the drug is still transferred afterwards. Dissolving the clot does not repair the narrowing underneath that caused it.

Part of my work as a Cardiologist takes me to Swan Hill, a town on the Murray River in Victoria, Australia. It is almost a five-hour drive from Melbourne, and I do that drive both ways. The hospital there is a good one, with excellent staff. What it does not have, and what most towns of its size anywhere in the world do not have, is a catheter laboratory: the room where a blocked heart artery can be reopened using a fine tube passed up from the wrist or groin.

A cardiac catheter laboratory, empty between procedures — A cardiac catheter laboratory. The table sits at the centre, an X-ray camera moves around the patient on a large arm above it, and the screens show the arteries in real time as the cardiologist works. Rooms like this are the reason a heart attack is treated differently depending on where it happens.

So when someone arrives there in the middle of a heart attack, a conversation starts almost immediately between the local team, the retrieval service, and a cardiologist somewhere else. Patients can be flown rather than driven, and retrieval teams are quick and well practised. Even so, the transfer takes time, and heart muscle is at risk while it happens. Do we move this person, or treat them here and move them afterwards?

Millions of people live somewhere that conversation would need to happen. It is worth understanding how it is resolved, because the answer is more reassuring than most people expect.

What Is Actually Happening in a Heart Attack

The heart is a muscle, and like every muscle it needs its own blood supply. Three main arteries sit on its surface and feed it.

Over years, fatty deposits can build up in the wall of one of those arteries. Most of the time they sit there quietly. A heart attack begins when the surface of one of these deposits ruptures. Your body reacts the way it reacts to any injury, by forming a clot to seal it. If that clot fills the artery completely, blood stops flowing.

Three stage diagram: a healthy artery with blood flowing freely, an artery narrowed by a fatty deposit, and an artery blocked by a clot after the deposit ruptures — How a heart attack begins: a fatty deposit narrows the artery over years, then its surface ruptures and a clot forms over it, Heart Matters

Beyond the blockage, that stretch of muscle is cut off from its supply. How much of it comes through depends almost entirely on how quickly the artery is reopened. Restore the flow early and most of the muscle is preserved. Leave it several hours and less of it is. That is the whole reason for the urgency.

An ECG, the tracing taken from stickers on your chest, shows this pattern clearly within minutes. Doctors have a name for it, a STEMI, and you may see that word on your discharge letter. All it means is that an artery is completely blocked and the clock is running.

Two Ways to Open the Artery

The first way is mechanical. A cardiologist passes a fine tube from the wrist or groin up to the heart, finds the blockage, pushes a small balloon through it, and usually leaves a stent behind to hold it open. This is angioplasty. Where it can be done promptly, it is the better option.

The second way is chemical. A drug goes into a vein and dissolves the clot from the inside. These are the medicines most people know as clot-busters, and they require no special equipment, no cardiologist, and no operating theatre. They can be given in a small emergency department, in an ambulance, or in the back of an aircraft.

Which one a person receives is decided by the clock, not by the quality of the hospital they happen to be standing in.

Watch: a closer look at the stent itself, and how it holds an artery open, Heart Matters Educational Series

Where the Clot-Busting Drugs Came From

For most of the twentieth century, doctors believed the clot in a heart attack formed after the muscle died rather than causing it. Dissolving it therefore looked pointless. That view held into the 1970s.

When it was finally overturned, the first drug tested properly was streptokinase, made from a protein produced by bacteria. In 1986 an Italian study of nearly 12,000 patients found it cut deaths by around a fifth. Two years later, a second large study showed that streptokinase helped, that plain aspirin helped, and that giving both together helped considerably more than either alone.

I would put those two studies among the handful that genuinely changed cardiology. Before them, a heart attack was something you watched. Afterwards, it was something you could interrupt.

Newer drugs followed through the 1990s, tested in trials involving well over 100,000 people between them. The differences between the drugs turned out to be small. The lesson that mattered was something else entirely.

Forty years of research pointed at the same conclusion. Which drug is used matters far less than how quickly it reaches the patient.

Angioplasty later proved better than drug treatment wherever both were genuinely available, and it became the preferred approach. What it could not do was shorten the road from a country town. That is why the drugs never went away, and why they are still given every week in hospitals like the one I visit.

How the Drug Works

Your blood already carries the tools to dismantle a clot. It keeps them switched off until they are needed, which is sensible, since a permanently active clot-dissolving system would be dangerous.

These drugs simply switch that system on. They do not attack the clot directly. They activate your own machinery, which then breaks apart the mesh of protein strands holding the clot together, and the blockage crumbles.

The older drug, streptokinase, switched the system on everywhere in the body at once. It worked, but it thinned the blood generally and sometimes caused allergic reactions.

The newer drugs, alteplase, reteplase, and tenecteplase, are more targeted. They act mainly where a clot already exists, which makes them safer and more effective, and current guidelines recommend them over the older one.

Tenecteplase has become the most widely used, for a very practical reason. It is a single injection given over about five seconds, rather than a drip running for an hour. In a small hospital preparing to move a patient, or in a helicopter, that difference matters enormously.

The Two-Hour Rule

Guidelines around the world agree on the threshold, which is reassuring given how differently health systems are organised.

If a team can get the artery open with angioplasty within roughly two hours of the moment medical help first reaches the patient, that is the route taken. If they cannot, and the person is within 12 hours of their symptoms starting, and there is no specific reason to avoid it, the drug is given without waiting.

2 hours
If angioplasty cannot be reached within roughly this window, giving the clot-dissolving drug first is the better option.
European Society of Cardiology and comparable international guidelines

Once that decision is made, the aim is to have the drug running within 30 minutes of arrival, and sooner where possible. Some ambulance and retrieval services now give it before the patient reaches hospital at all.

The benefit is greatest in the first two or three hours after symptoms begin and fades steadily after that. Beyond about 12 hours there is little left to gain, and the balance shifts back towards transferring the person for angioplasty however far away it is.

What We Check Before Giving It

A clot-dissolving drug cannot tell the difference between a clot that is causing a heart attack and a clot somewhere else that is quietly doing something useful. That is the trade-off, and it is why this treatment carries a bleeding risk that angioplasty does not.

The serious concern is bleeding into the brain. It is uncommon, affecting somewhere around one in 100 people treated or fewer, but it can be devastating when it occurs. The risk is higher in older patients, in very small patients, and where blood pressure is high and not yet controlled.

So before giving it, the team works through a set of questions. Some answers rule the drug out completely. These include any previous bleed into the brain, a stroke caused by a blockage within the last six months, a known weakness or tumour in the brain’s blood vessels, major surgery or a serious head injury in the past month, bleeding from the stomach or bowel in the past month, a known bleeding disorder, or a suspected tear in the body’s main artery.

Other answers do not rule it out but change the balance. Advanced age, a recent fall, pregnancy, a stomach ulcer, or blood pressure that is very high all fall into this group, and they are weighed against how large the heart attack is and what the alternative would involve.

Where the drug genuinely cannot be given, the person is transferred for angioplasty no matter how long the journey takes. That decision gets made quickly, and it is one of the reasons the phone call happens early.

Bruising and minor bleeding around drip sites are common and rarely amount to anything.

Why the Journey Still Happens Afterwards

This part surprises people, and it is the single most useful thing to understand about the whole pathway.

The drug dissolves the clot. It does nothing at all to the fatty deposit underneath that ruptured in the first place. That deposit is still there, still narrowing the artery, and still capable of triggering another clot. Opening the artery buys time. It does not finish the job.

For that reason, guidelines say that essentially everyone who receives the drug should still be moved to a hospital with a catheter laboratory, even when the treatment has clearly worked.

The diagnosis

The ECG confirms a blocked artery. The team works out how long it would realistically take to reach a catheter laboratory, usually with the retrieval service already on the phone.

The treatment

If that journey would take more than about two hours, the drug is given, along with aspirin and other medicines that stop the clot reforming.

Checking it worked

Around an hour to 90 minutes later the ECG is repeated. If the pattern has settled substantially, the artery has almost certainly opened. Chest pain usually eases at the same time.

If it did not work

If the artery has stayed blocked, or the person becomes unwell, transfer happens straight away for urgent angioplasty rather than waiting.

The planned transfer

If it did work, transfer still happens, with a coronary angiogram usually done between two and 24 hours later, and a stent placed if one is needed.

That timing was not chosen arbitrarily. Going to the catheter laboratory immediately after the drug was tested and caused more bleeding without extra benefit. Waiting several days risked the artery closing again. Somewhere between a few hours and a day turned out to be the sweet spot.

The Part That Matters Most

Across every study ever done in this area, the factor with the biggest effect on how someone does has never been which drug they got or which hospital they reached.

It has been how long they waited before calling for help.

That gap is measured in hours in most countries. It is the only part of the whole sequence that happens before any doctor, nurse, or paramedic is involved, and it is the part most people underestimate. Someone with chest discomfort at 11pm who decides to see how they feel in the morning has already spent the window in which either treatment works best, whether they live next door to a major hospital or five hours from one.

Delay is longer still when the symptoms do not match the picture people carry in their heads. Women in particular are more likely to present with breathlessness, nausea, or exhaustion rather than crushing chest pain, and are more likely to wait, and to be waited on, as a result.

None of which is a failing on anyone’s part. Chest symptoms are frequently vague, they rarely arrive at a convenient moment, and not wanting to make a fuss is among the most human responses there is. It is worth knowing that ambulance services would far rather be called early and turn out to be unnecessary than be called too late.

Call your local emergency number straight away if any of these occur. Do not drive yourself, and do not wait to see whether it settles.

Chest pain, pressure, tightness, or heaviness lasting more than 10 to 15 minutes.
Discomfort spreading into the arm, jaw, neck, back, or upper stomach.
Sudden breathlessness, a cold sweat, nausea, or feeling faint alongside any of the above.

Symptoms are often less obvious in women, in people with diabetes, and in older adults. Breathlessness or sudden overwhelming tiredness without any chest pain still warrants an emergency call. An ambulance crew can record an ECG on the spot, warn the hospital you are coming, and start treatment on the way, none of which happens if you drive.

Watch: what recovery after a heart attack usually involves, and the questions people most often have afterwards, Heart Matters Educational Series

Conclusion

Clot-busting treatment is not a lesser version of modern heart attack care. It is the treatment that created modern heart attack care, and in the right circumstances it remains the better of the two options rather than the fallback. A drug given at 40 minutes in a country hospital does more good than a flawless angioplasty four hours later.

What matters most is the early hours rather than the map. And if you are reading this because it has already happened, to you or to someone you love, the thing I would want you to take from it is that being treated a long way from a major centre does not mean you were given second best. I have written elsewhere about what recovery usually involves, and your own cardiologist can fill in what is specific to you. But whatever the past few weeks have looked like, the distance did not decide this, and that is worth holding onto.

Pericarditis: Chest Pain That’s Worse Lying Down

July 31, 2026

Key Points

Pericarditis is inflammation of the thin sac surrounding the heart. It is one of the more common causes of chest pain in younger people and, in most cases, one of the least dangerous.
The pain has a distinctive signature. It typically sharpens when lying flat and eases on sitting forward, which is unusual enough to be a useful clue.
In most cases no cause is ever found, or the illness follows an ordinary virus. Where tuberculosis is common, it is a leading cause and the picture differs. Where a specific cause does turn up, it changes both the outlook and the treatment.
Anti-inflammatory treatment combined with colchicine is standard first-line practice. In trial data, adding colchicine roughly halved the chance of the condition returning.
Recurrence is the most common complication, affecting somewhere between 15% and 30% of people after a first episode. Serious complications are uncommon. Where no underlying cause is found, fewer than 1 in 100 people go on to develop lasting stiffening of the sac.

The pain arrives sharply, usually behind the breastbone, and it behaves in a way that heart pain is not supposed to behave. Lying down makes it worse. Sitting up and leaning forward makes it better. Taking a deep breath can be enough to catch it.

That pattern sends many people to an emergency department convinced they are having a heart attack, and it is also why the diagnosis is often made quickly once someone describes it. Few cardiac symptoms are as positionally specific.

It tends to affect people younger than the typical coronary patient, and the outlook for most is good. What follows is what the condition actually is, why it happens, and what the evidence supports doing about it.

What the Pericardium Does

The heart sits inside a two-layered sac called the pericardium. Between the layers is a small amount of fluid, usually only 15 to 50 mL, which allows the heart to move smoothly against surrounding structures with every beat.

The sac anchors the heart, provides a barrier against infection spreading from the lungs, and stops the heart stretching too far. It is not essential to survival, and people who have had it surgically removed generally do well.

When it becomes inflamed, two things follow. The layers lose their smooth glide and rub against each other, which produces pain. Inflammation can also draw extra fluid into the space between the layers. Doctors call that a pericardial effusion, which simply means a build-up of fluid around the heart.

Cross-section of the heart showing the pericardium: the fibrous pericardium, parietal layer, pericardial fluid, visceral layer or epicardium, and the heart muscle beneath. Layer thickness is exaggerated for clarity. — The pericardium is a two-layered sac. Layer thickness is exaggerated in the drawing so each layer can be told apart; in reality the whole wall is only a couple of millimetres thick.

Fibrous pericardium, the outer layer. The tough outside of the sac. It anchors the heart in place and stops it stretching too far.

Parietal layer, the outer lining. The smooth inside surface of the outer sac.

Pericardial fluid. Normally only 15 to 50 mL, enough for the surfaces to glide. Inflammation can increase it, and the build-up is called an effusion.

Visceral layer, the inner lining. The same thin membrane as layer 2, folded back on itself and stuck to the heart’s own surface. Its medical name is the epicardium.

Heart muscle. Sits beneath the sac and is not affected in straightforward pericarditis. Doctors call it the myocardium.

What It Feels Like

The pain has a recognisable pattern

The pain is sharp rather than heavy, sits centrally behind the breastbone, and often radiates to the neck, the left shoulder, or the ridge of muscle running along the top of the shoulder. That last spot is unusual, and when it happens it is a fairly strong clue.

What sets it apart is how it responds to position and breathing. Lying flat brings the inflamed layers into closer contact and intensifies the pain. Sitting upright and leaning forward relieves it. Deep breaths, coughing, or swallowing often make it worse.

This is close to the opposite of the pain of a heart attack, which is typically a pressure or heaviness, unaffected by position, and frequently accompanied by sweating and nausea. The distinction is useful but not absolute, which is why chest pain of any kind is assessed rather than self-diagnosed.

Other symptoms

A low-grade fever is common, particularly where a viral illness preceded the episode. Fatigue, breathlessness, and a general sense of being unwell frequently accompany the pain, and symptoms tend to build over hours rather than striking instantaneously.

Watch: Prof. Peter Barlis on pericarditis, Heart Matters Educational Series

How the Diagnosis Is Made

European guidelines define acute pericarditis by the presence of at least two of four features: the characteristic chest pain, a particular sound heard through the stethoscope, specific changes on the heart tracing, and new or increasing fluid around the heart.

That sound has a name, a pericardial friction rub, and it is exactly what it sounds like: a scratching or creaking made by the inflamed layers rubbing together. Hearing it points strongly to the diagnosis. It comes and goes, though, so not hearing it rules nothing out.

No single test confirms it. The diagnosis is assembled from several, each answering a different question.

Test	What it looks for	In pericarditis
ECG	The heart’s electrical signal	Widespread, not one artery
Echocardiogram	Fluid around the heart	Effusion, filling affected
CRP	Inflammation in the body	Raised, tracks response
Troponin	Damage to heart muscle	Raised if muscle involved
Cardiac MRI	Inflammation, seen directly	Used when unclear

The ECG point is the one that separates pericarditis from a heart attack most reliably. Its changes are widespread rather than confined to the territory of a single artery. Troponin matters for a different reason. It is a protein released when heart muscle is damaged, so a raised level means the muscle is inflamed alongside the sac. That combination has its own name, myopericarditis, and it is watched more closely.

What Causes It

Most often, no cause is ever found

Where tuberculosis is uncommon, most cases fall into one of two groups: no cause found, or an ordinary virus assumed to be behind it. Doctors label the first group idiopathic, which is simply the medical word for cause unknown.

The two groups blur into each other. Many of the unexplained cases were almost certainly viral all along, with no test ever done to pin down which virus, largely because finding out rarely changes the treatment.

The viruses involved are everyday ones: the family behind common colds and stomach upsets, influenza, and the virus that causes glandular fever. A chest or stomach bug in the few weeks beforehand is a common part of the story.

That is why guidelines in low-tuberculosis regions do not push for exhaustive testing in every case: the search seldom finds anything and the usual causes settle on their own. Where tuberculosis rates are high, it becomes the leading cause of pericarditis and the approach changes completely.

COVID-19 and the vaccine question

This deserves a direct answer rather than a careful silence, because it is what many readers arrive looking for.

Both COVID-19 itself and the mRNA COVID vaccines have been linked to inflammation of the sac and of the heart muscle. Both associations are real. They differ substantially in magnitude.

Analyses of national reporting systems have estimated roughly six cases of heart or sac inflammation per million vaccine doses given, across all ages. Risk concentrates heavily in one group: young males, after the second dose, with estimates of around 12 to 13 cases per million doses in those aged 12 to 39. In adolescent studies, the risk after a second dose has been several times higher than after a first, and considerably higher in males than females. Most cases have been mild and settled with standard treatment.

Catching the virus carries the higher risk. A Hong Kong population study found this inflammation in roughly 326 per million people with confirmed COVID-19, against about 5.5 per million among those vaccinated, the latter being no different from the pre-pandemic background rate. A Spanish hospital study reported the same direction of effect, with the incidence following infection around 20 times that following mRNA vaccination. Cases attributed to infection also tended to be more severe.

Estimates vary between studies according to population, age structure, case definition, and how thoroughly cases were sought, so the precise figures should be read as an order of magnitude rather than a fixed number. The consistent finding across countries is the direction of the comparison. The risk is real on both sides, is counted in cases per million on both sides, and is higher after infection than after vaccination.

None of this makes an individual case less real or less unpleasant for the person experiencing it. Someone who develops pericarditis after a vaccine dose has a genuine condition requiring genuine treatment, and population-level reassurance is not an answer to an individual’s symptoms.

The causes at a glance

No cause found

Nothing is ever pinned down. This is the biggest single group, and it is also the one that settles most easily. Doctors call it idiopathic.

Viral illness

Everyday viruses: colds, stomach bugs, influenza, glandular fever. A chest or stomach illness in the previous few weeks is a common part of the story.

COVID and vaccination

Both infection and mRNA vaccination have been linked to it. Both are counted in cases per million, and the figure is higher after infection. See the section above.

Injury to the heart

After a heart attack, heart surgery, or a procedure done through a tube in an artery. The sac reacts to the injury nearby.

Autoimmune and systemic

Conditions where the immune system attacks the body’s own tissues, such as lupus and rheumatoid arthritis. Also kidney failure, some cancers, radiation treatment to the chest, and certain medicines.

Bacterial and tuberculous

Bacterial infection or tuberculosis. Far less frequent where tuberculosis rates are low, but wherever it occurs the outlook is considerably worse and lasting stiffening of the sac is far more likely.

How It Is Treated

Clinicians work through a fairly settled sequence. Most people never get past the first step of it.

Treatment	Where it fits	Typical duration
Aspirin or ibuprofen	First choice, for the pain	Until symptoms settle
Colchicine	Added to the first choice	3 months, 6 if it returns
Steroid tablets	Where the first two are unsuitable	Reduced slowly
Anakinra, rilonacept	Repeated relapses only	Specialist supervision

Dose and duration are individual. Only the prescribing doctor, who knows the specific circumstances, can determine what is appropriate for a given person.

Two things in that table are worth expanding on.

Colchicine earns its place. The evidence is unusually strong for a condition this common. In the ICAP trial, people having a first episode were randomly given either colchicine or a dummy tablet alongside their usual treatment. The illness persisted or came back in 16.7% of those on colchicine, against 37.5% on the dummy tablet. Looking at return of symptoms alone, the figures were 9.2% against 20.8%. Stomach and bowel side effects were no more common than with the dummy tablet.

Steroids sit third for a reason. They work quickly, which makes their position in the list counter-intuitive. But steroids used during a first attack have been linked to a higher chance of the problem returning, so the medicine that settles things fastest can make the months afterwards harder. They are generally kept for people who cannot take the first two options, or where an immune condition is being treated, and only once infection has been ruled out.

Under 1% get a stiff sac

Where the cause is unknown or viral. The figure rises sharply where bacteria or tuberculosis are responsible.

15% to 30% recur

Recurrence is the most common complication after a first episode, and the figure is higher again without colchicine.

Colchicine halves recurrence

In the ICAP trial, the illness came back or persisted in 16.7% on colchicine, against 37.5% on a dummy tablet.

When It Comes Back

Recurrence is the most common complication and the most frustrating part of the condition. Between 15% and 30% of people experience a recurrence after a first episode, and among those who go on to have a first recurrence, the chance of a further one rises towards 50%.

A recurrence means a fresh episode after four to six weeks with no symptoms at all. The best explanation is that the immune system keeps the reaction running long after whatever set it off has gone. That is why medicines aimed at the immune signal itself work when they do.

The reassuring part, and it is worth stating plainly because people with repeated episodes often assume the opposite, is that recurrence does not signal accumulating damage. In groups of patients followed through repeated unexplained episodes, lasting stiffening of the sac has not been reported at all, and the overall risk in this group looks lower than after a single first episode.

The Complications That Matter

Two complications account for most of the concern.

Fluid squeezing the heart. If fluid gathers quickly enough, or in a large enough volume, it presses on the heart and stops it filling properly. The medical name is cardiac tamponade. It is rare where no cause is found, and much more common where cancer, tuberculosis or bacterial infection is behind the illness. Treatment is to drain the fluid.

A sac that turns stiff. Long-running inflammation can leave the sac thickened and rigid, so it grips the heart like a shell and limits every beat. The medical name is constrictive pericarditis. The risk is under 1% where the cause was unknown or viral, 2% to 5% for immune and cancer-related causes, and 20% to 30% where bacteria or tuberculosis were responsible.

Signs that warrant urgent medical attention include fainting, rapid or laboured breathing, severe or escalating breathlessness, or a sudden deterioration. These can be signs of fluid building up and squeezing the heart. Anyone experiencing them should seek emergency care immediately rather than waiting for a scheduled appointment.

Conclusion

Pericarditis is a condition where the alarming presentation and the actual outlook are poorly matched. The pain is genuinely severe, it mimics a heart attack closely enough to send people to hospital, and yet the great majority of cases settle with anti-inflammatory treatment and leave nothing behind.

Two things most influence how it goes: whether an underlying cause is identified, which changes the outlook substantially, and whether colchicine forms part of the initial treatment, which roughly halves the chance of it returning. For a diagnosis that so often arrives frightening, that is an encouraging picture.

When Blood Pressure Won’t Come Down: What Happens Next

July 29, 2026

Managing resistant hypertension — blood pressure monitoring and medication options explained by Prof. Peter Barlis

Blood pressure that stays high despite three or more medications has a name, and in most cases an explanation. What clinicians check first, why spironolactone is usually the fourth medicine added, and how narrow the role of renal denervation really is.

The Hair Loss Question

July 29, 2026July 29, 2026

Key Points

Several medicines used in cardiology overlap with medicines used for hair, in both directions, which is why questions about hair loss often land with a cardiologist rather than a dermatologist.
Minoxidil, the treatment most people are asking about, began life as a blood pressure drug. The scalp solution rarely troubles the heart. The tablets retain a diluted version of the original effects.
Spironolactone, prescribed for heart failure and difficult blood pressure, also blocks the effects of male hormones. That is why it is used off-label for female pattern hair loss, and why some women notice a change in their hair while taking it.
The same hormonal effect makes spironolactone an unsuitable hair treatment for men, and this is the point most often missed.
Some hair loss is a signal rather than a cosmetic problem, including the shedding that commonly follows a heart attack, cardiac surgery, or any serious illness.

It is fair to wonder why a cardiologist is being asked about hair at all. The answer is that patients are increasingly being sent to ask.

Hair clinics and general practices now routinely tell people to check with their doctor about their heart before starting treatment, particularly minoxidil tablets. It arrives as a safety clearance rather than a cosmetic query, and it lands in a cardiology room because that is where it was sent.

There is a sound reason for that. Minoxidil was a blood pressure medicine long before it was a hair treatment, and it never entirely stopped being one. The overlap also runs the other way, because one of the medicines already sitting on many cardiac prescription lists is used by dermatologists for exactly this purpose.

Which is why the question, when it does come, is usually asked apologetically at the very end of the appointment, halfway out of the chair. It does not need to be. It is a question about medicines, and it belongs here.

Minoxidil, the One People Are Sent to Ask About

This is the treatment behind most of the clearance requests, and it has its own cardiovascular history.

It reached the market in the late 1970s as a treatment for severe hypertension. Patients taking it grew hair, and a topical formulation followed in the 1980s. Brand names differ from country to country, so the generic name minoxidil remains the reliable identifier on any packet, and available strengths vary by market.

Minoxidil opens potassium channels in the smooth muscle of small arteries. Those vessels relax and blood pressure falls. The body compensates by retaining salt and water and by raising the heart rate, which is why minoxidil tablets at blood pressure doses were almost always paired with a diuretic and a beta-blocker.

The scalp solution

Applied to intact scalp, only a small proportion of a topical dose reaches the bloodstream, far too little in most people to move blood pressure or heart rate measurably. Palpitations, lightheadedness, and mild ankle swelling have been described, but they are uncommon and tend to follow generous application, use over inflamed or broken skin, or unusual sensitivity to vasodilators.

Low-dose tablets

The bigger change over the past few years has been dermatologists prescribing minoxidil tablets at low doses, a small fraction of the intensity once used for hypertension. The largest published safety experience, a review of 1,404 patients across 10 centres in six countries, found side effects that were mostly mild. Hair growth in unwanted places was by far the most common, affecting about 15% of patients. Lightheadedness, fluid retention, and a faster heart rate each appeared in under 2%, and fewer than one in 50 people stopped treatment because of a side effect.

Hair in other places

The most frequently reported effect. Fine hair on the face, forearms, or upper back. It is not dangerous and it settles once the tablet is stopped.

Fluid retention

Salt and water retention is built into how the drug works. It shows up as puffy ankles or a small rise in weight, and it matters far more in a heart that is already struggling.

Heart rate and blood pressure

A slightly faster resting pulse and a small fall in blood pressure are both expected. People already taking several blood pressure medicines feel this more.

Where the frightening warnings came from

Anyone reading the product information for minoxidil tablets will find warnings about fluid collecting around the heart and about angina becoming worse. These are real, and they are also a product of their era, written from experience with high-dose treatment in patients who had severe hypertension, often alongside significant kidney disease, before modern blood pressure regimens existed. Pericardial effusion, meaning fluid in the sac surrounding the heart, was described in that setting and is identified on an echocardiogram.

At the doses used for hair, events of that severity appear to be rare rather than routine. Rare is not the same as impossible. The fair summary is that low-dose oral minoxidil has a reassuring short-term record in relatively healthy people, and a much thinner evidence base in those with established heart disease, because they are the patients least likely to have been studied.

Minoxidil at blood pressure doses also carries a rebound risk. Stopping abruptly removes the vasodilation while the compensating fluid retention and faster heart rate are still present, and blood pressure can overshoot. That is why the dose is usually stepped down rather than halted outright. Whether, when, and how to stop is a decision for the prescribing doctor, who may reasonably choose to stop immediately if a serious effect appears.

Feature	Topical	Low-Dose Oral
Brand names (vary by country)	Several major brands	Usually generic tablets
Reaches the bloodstream	A small percentage	Effectively all of it
Availability	Over the counter in most markets	Prescription, and off-label
Common nuisance effects	Scalp irritation and itching	Unwanted hair, puffy ankles
Cardiovascular relevance	Low for most people	Modest, worth reviewing
Dose strengths	Vary by market	Far below blood pressure doses

The situations that usually prompt a fuller review before oral minoxidil is considered are heart failure, known pericardial disease, significant valve disease, pulmonary hypertension, recent unstable angina, reduced kidney function, and a blood pressure regimen that is already crowded. In that last group, home blood pressure readings become genuinely useful information.

Spironolactone, the Medicine Already on the List

Spironolactone is a familiar name in cardiology. It is a mainstay of treatment in heart failure with reduced ejection fraction and one of the more useful options when blood pressure refuses to come down on three other agents.

Less widely known is that it does two things at once. Alongside its effect on salt and water handling, it blocks androgen receptors and reduces the production of male hormones. Androgens are central to pattern hair loss, which is why dermatologists reach for spironolactone in female pattern hair loss, acne, and polycystic ovary syndrome.

So a woman taking spironolactone for her heart who reports that her hair seems less thin is not imagining a mechanism. There is a plausible one, and it is the same mechanism a dermatologist would have been aiming for deliberately.

What the evidence actually supports

The evidence here is honest but modest. Most of it comes from observational series and clinical consensus rather than large randomised trials, and it points toward a partial effect that develops slowly, over many months, in some women rather than all of them. That is worth taking seriously. It is not a promise.

The doses are not the same

There is a further complication. The doses commonly used in dermatology sit above those used in heart failure, where treatment is deliberately conservative to protect kidney function and potassium levels.

Someone taking spironolactone for a cardiac reason is therefore receiving an amount that may or may not be doing much for their hair. A welcome side effect is a reasonable thing to enjoy. It is not a reason to start the drug, or to want more of it.

Why this is a different conversation for men

This is the point that gets lost fastest once the phrase “spironolactone helps hair” is in circulation.

Blocking androgens has consequences that men notice. Breast tenderness and breast tissue enlargement, known as gynaecomastia, are well recognised and become more likely at higher doses. Reduced libido is also reported. These are the reasons spironolactone is not used as a hair loss treatment in men.

Men already prescribed it for heart failure are a separate matter. There the cardiac benefit is substantial and well established, and the hormonal effects are managed as a known trade-off rather than pursued.

Potassium, and the combinations that matter

Spironolactone causes the body to retain potassium. That is intrinsic to how it works, and in most people it is handled without difficulty.

It becomes more delicate in combination. ACE inhibitors, angiotensin receptor blockers, sacubitril with valsartan, potassium supplements, and some anti-inflammatory painkillers all push potassium in the same direction, and reduced kidney function narrows the margin further. Blood tests before starting and at intervals afterwards are the standard way this is monitored, and they are the reason spironolactone is prescribed rather than borrowed from a relative’s cabinet.

Spironolactone is also avoided in pregnancy, because an antiandrogen affects a developing baby.

Finasteride and dutasteride, the other treatments raised most often, work on hormone conversion rather than on blood vessels. No consistent cardiovascular signal has emerged from the trial data, and the discussions around them concern sexual side effects and mood rather than the heart.

The GLP-1 Question

A study published in The BMJ in July 2026 looked at this directly. Researchers followed adults with type 2 diabetes starting a GLP-1 receptor agonist and compared them with people starting two other classes of glucose-lowering medicine. Newly recorded hair loss was more common in the GLP-1 group, by roughly 40% to 70% depending on the comparison.

Three things temper that. The absolute numbers were small, at around seven cases per 1,000 people a year against four to five in the comparison groups. The excess was concentrated in non-scarring hair loss, the diffuse and usually reversible kind linked to rapid weight change. And a study built on diagnoses recorded during routine care cannot fully separate an effect of the drug from an effect of losing weight quickly.

The study was done in one large health system and in people with diabetes, so it does not settle the question for everyone taking these medicines. It matters here because semaglutide and related medicines are now prescribed for cardiovascular reasons and not only metabolic ones. An effect on hair that is usually reversible sits on a very different scale from a reduction in heart attacks and strokes.

When Hair Loss Is a Signal Rather Than a Complaint

Not all hair loss is pattern baldness, and some of it points back toward the heart. A heart attack, cardiac surgery, or any major physiological stress can push a large proportion of hair follicles into their resting phase at once. The shedding arrives two to four months later, by which time most people have stopped connecting the two events.

Growing

Most follicles.
Lasts years.

Resting

A small minority.
Root pulls upward.

Shedding

Follicle empties,
then restarts.

Resting to shedding takes two to four months

A shock to the body pushes many follicles into the resting phase together, so they shed as a group months after the event.

Iron deficiency and thyroid disease belong in the same category. Both cause hair loss, both are common in people with heart disease, and both are treatable once found.

Questions Patients Ask Me Most

These are the ones that come up again and again in clinic, answered as plainly as I can. As always, this is general information, and any decision about your own medicines belongs in a conversation with your doctor.

Can I use the scalp solution if I have a heart condition?

Mostly reassuring

For most people with stable heart disease, topical minoxidil is not the thing a cardiologist is concerned about. Very little of it reaches the bloodstream through intact scalp. It is still worth mentioning at your next appointment, particularly if you have heart failure or your blood pressure is being actively adjusted.

I am already on spironolactone. Will it help my hair?

Worth discussing

It might, if you are a woman with pattern hair loss, and some women do notice a change. The effect is partial, gradual, and not universal, and the doses used in dermatology usually sit above cardiac doses. It is a welcome bonus if it happens, rather than something to count on or to ask for more of.

If it works for women, can a man take it for hair?

Worth discussing

Spironolactone is not used as a hair treatment in men. The same hormone blocking that helps some women causes breast tenderness and breast tissue enlargement in men, and reduced libido is also reported. Men taking spironolactone for heart failure are in a different situation, where the cardiac benefit is the point.

My hair started falling out after my heart attack. Is it the medication?

Mostly reassuring

Usually not. Shedding that begins two to four months after a heart attack, cardiac surgery, or a serious illness is far more often telogen effluvium, the body’s delayed response to the stress itself. It is diffuse rather than patchy and it recovers on its own in most cases. Iron levels and thyroid function are worth checking.

Should I stop my weight loss injection if my hair thins?

Worth discussing

That is a conversation to have rather than a decision to make alone. The hair loss described with these medicines is the reversible kind and the absolute risk is small, while the cardiovascular benefit for people who qualify is substantial. Stopping a medicine prescribed to reduce heart attacks and strokes is not a step to take over hair without advice.

Is there anything worth checking before I try something?

Mostly reassuring

Iron studies and thyroid function are the two most commonly useful tests, because both cause hair loss, both are common in people with heart disease, and both are treatable. Kidney function and potassium matter if spironolactone is being considered. These are simple blood tests rather than anything elaborate.

Heart Matters Resource

When in Doubt, Get Checked Out

New swelling, unexplained weight gain, or a racing pulse after starting any new medicine are worth reviewing properly rather than waiting to see whether they settle.

Read: When in Doubt, Get Checked Out →

Conclusion

Hair and the heart share more pharmacology than either specialty tends to advertise. One widely used cardiac medicine has a genuine effect on hair in women and a set of reasons not to use it that way in men. The best known hair treatment was a blood pressure drug first and never entirely stopped being one.

So when a hair clinic or a GP sends someone to have their heart checked before starting treatment, that is a sensible instruction rather than a formality. For most people the answer will be straightforward. Knowing which people it is not straightforward for is the reason the question is worth asking at all.

Aortic Dissection: The Chest Pain That Cannot Wait

July 17, 2026

Key Points

An aortic dissection is a tear in the wall of the aorta, the body’s main artery. It is a medical emergency, and every minute counts.
The warning sign is sudden, severe chest or back pain, often described as ripping or tearing, and often the worst pain a person has ever felt. It arrives at full intensity within seconds rather than building gradually.
Long term high blood pressure is the single biggest risk factor. Most people who have a dissection have had raised blood pressure for years.
Inherited conditions such as Marfan syndrome, and a family history of aortic aneurysm or unexplained sudden death, substantially increase risk and are a reason to ask about screening.
Dissection is easily mistaken for other conditions, and a normal ECG or normal blood test does not rule it out. If the pain fits the pattern, call 000.

Most cardiac emergencies announce themselves gradually. A heaviness in the chest that builds over minutes. A tightness that comes on with exertion and eases with rest. An aortic dissection does not behave this way. It arrives at full force, without warning, in people who felt perfectly well moments earlier.

It is the emergency that gives no notice. A person is well in the morning, well over lunch, and in cardiac arrest by the evening. That pattern is not a rare exception to how dissection behaves. It is characteristic of it.

Understanding what an aortic dissection is, who is at risk, and above all what it feels like, is the difference between a call to emergency services and a fatal delay.

What Is an Aortic Dissection?

The aorta is the largest blood vessel in the body. It leaves the heart, arches over the top of it, and travels down through the chest and abdomen, carrying every drop of blood the heart pumps out to the rest of the body. It is roughly the width of a garden hose, and it withstands enormous pressure with every heartbeat.

The wall of the aorta is made of three layers, bonded together. A dissection begins when the innermost layer develops a tear. Blood, travelling at high pressure, is forced into that tear and begins to push the layers apart, carving a false channel along the length of the vessel.

Once that channel opens, several things can go badly wrong at once. The false channel can compress the true one, starving organs of blood. It can extend into the branches that supply the brain, kidneys, or the heart muscle itself. It can rupture entirely. And if the tear is close to the heart, blood can leak into the sac that surrounds it, squeezing the heart until it can no longer pump.

The Two Types, and Why the Difference Matters

Doctors classify dissections by where the tear sits. This is not academic. The two types are treated in fundamentally different ways.

Type A dissections involve the ascending aorta, the section closest to the heart. These are surgical emergencies. The tear can extend backwards into the sac around the heart or shear off the arteries feeding the heart muscle, and either can cause sudden cardiac arrest. Type A dissections are taken directly to theatre.

Type B dissections are confined to the descending aorta, further down the chest. These are often managed initially with aggressive blood pressure control in intensive care, with a stent placed inside the vessel in selected cases. Surgery is not always the first step.

Type A

The tear involves the section of aorta nearest the heart. This is the more dangerous form and is treated as an immediate surgical emergency.

Type B

The tear is confined to the descending aorta, further from the heart. Often managed first with intensive blood pressure control, and sometimes a stent.

Why Time Matters

For an untreated Type A dissection, the risk of death rises with every hour that passes after the tear. This is why it is never something to wait out.

What It Actually Feels Like

This is the section worth remembering, because recognising the pain is what gets people to hospital in time.

The classic symptom is sudden, severe pain in the chest or back. Patients describe it as ripping, tearing, or being stabbed. It is frequently described as the worst pain of their life. Two features set it apart from most other chest pain.

First, the onset. It does not build. It is maximal within seconds. People can often tell you exactly what they were doing at the moment it began.

Second, it can move. As the tear extends along the vessel, the pain can travel, migrating from the front of the chest through to between the shoulder blades, or down into the abdomen.

Dissection can also present in ways that look like something else entirely. Stroke-like symptoms if the tear reaches the arteries to the brain. Abdominal pain. Fainting. A leg that suddenly turns cold and pale. In the most severe cases, the first sign is collapse. This was the pattern in the widely reported death of United States Senator Lindsey Graham in July 2026, whose office cited preliminary findings of an aortic dissection due to arteriosclerotic cardiovascular disease. He was 71, had recently returned from an overseas trip, and had shown no sign of being unwell.

Chest pain that arrives at full intensity in an instant, and is described as tearing or ripping, is not a wait and see symptom. It is a call an ambulance symptom.

Why Blood Pressure Sits at the Centre of This

The most important thing to understand about dissection is that in the majority of cases, it is the endpoint of a process that has been building quietly for years.

Every heartbeat sends a pulse of pressure through the aortic wall. Over decades, persistently high blood pressure stresses that wall, stiffening it and degrading the elastic tissue that holds the layers together. Add the plaque and inflammation of atherosclerosis, the same disease process that drives most heart attacks and strokes, and the wall becomes progressively less able to tolerate the pressure it is subjected to.

Chronic hypertension is the single biggest modifiable risk factor for aortic dissection, and it is present in the large majority of cases. This is the uncomfortable but hopeful part of the story. A condition that kills within minutes is driven, more than anything else, by a number that can be measured at home in 60 seconds and treated effectively.

The other well-recognised contributors are:

Age and sex. Dissection most commonly affects men in their 60s and 70s, though it can occur far younger, particularly where there is an inherited cause.
Smoking. Tobacco accelerates the arterial damage that weakens the aortic wall.
An existing aortic aneurysm. A vessel that has already enlarged is a vessel more likely to tear.
Stimulant drug use. Cocaine and amphetamines cause abrupt, extreme blood pressure surges.
Pregnancy. Uncommon, but a recognised period of increased risk in women with underlying aortic disease.

The Genetic Side, and When Family History Matters

Not every dissection is a story about decades of blood pressure. A meaningful minority occur in younger people whose aortas were structurally vulnerable from birth.

Inherited connective tissue conditions

Marfan syndrome is the best known. It affects the connective tissue that gives the aortic wall its strength, and people with Marfan syndrome can experience dissection in their 30s or 40s. Loeys-Dietz syndrome and vascular Ehlers-Danlos syndrome carry similar risk. These conditions often, though not always, come with recognisable physical features such as tall stature, long limbs and fingers, and problems with the lens of the eye.

Bicuspid aortic valve

Some people are born with an aortic valve that has two leaflets instead of the usual three. This is one of the most common congenital heart differences, and it is associated with weakness in the wall of the ascending aorta, independent of any valve problem. It is also relevant to aortic stenosis later in life.

Familial aortic disease with no syndrome attached

This is the group most often missed. Some families carry a tendency to aortic aneurysm and dissection without any of the classical syndromes and without any outward clues. The only signal is the family history itself.

If a parent, sibling, or child has had an aortic aneurysm, an aortic dissection, or an unexplained sudden death, that is worth raising with your doctor. Imaging can measure the size of the aorta long before it is in danger, and an aorta that is enlarging can be monitored, treated with blood pressure medication, and repaired electively. Elective repair is a very different proposition to emergency surgery on a tearing vessel.

Why It Is So Easily Missed

Aortic dissection is one of medicine’s great imitators, and this is worth understanding because it affects what you should do.

The standard tests used to assess chest pain, an ECG and a blood test for cardiac enzymes, can be entirely normal while the aorta is tearing. A chest X-ray is often unremarkable. The diagnosis usually rests on a CT scan of the aorta, and that scan only gets ordered if someone thinks to order it.

This has two practical implications. If you experience sudden tearing chest or back pain, say so in exactly those words to the paramedics and to the doctor in the emergency department. The description matters. And if you have a family history of aortic disease, say that too, unprompted. It changes how the pain in front of the doctor is interpreted.

It is entirely reasonable, in that situation, to ask directly whether an aortic dissection has been considered. Good clinicians will not be offended by the question.

What You Can Actually Do

The measures that protect the aorta are not exotic. They are the same measures that protect the rest of the cardiovascular system, applied consistently over years.

Know your blood pressure and treat it. If you have been prescribed medication for it, take it. This matters more than any other single action, and there is a great deal you can do alongside medication to help bring the numbers down.

Do not smoke. Treat raised cholesterol. Stay physically active. Understand your overall cardiovascular risk profile rather than any single number in isolation.

And know the alarm symptom. Sudden, severe, tearing chest or back pain, arriving at full intensity, in a person who was well moments before, is an emergency until proven otherwise. In Australia, call 000. Do not drive yourself. Do not wait to see whether it settles.

Conclusion

An aortic dissection is one of the few conditions in cardiovascular medicine where outcome is measured in minutes rather than hours or days. It is also, for most people, the final chapter of a much longer and much quieter story, one written by years of untreated blood pressure and arterial damage. That is the part that is within reach.

Take the blood pressure reading. Ask about the family history. And if the pain ever comes, sudden and tearing and unlike anything before it, do not talk yourself out of the phone call.

Cardiac Amyloidosis: The Stiff Heart Condition That’s Now Treatable

July 13, 2026

Cardiac amyloidosis is caused by misfolded proteins stiffening the heart muscle, and it is now treatable. Here is what patients need to know about this increasingly recognised and now treatable condition.

Demystifying Heart Failure: HFrEF, HFpEF and HFimpEF Explained

July 9, 2026

Key Points

Heart failure does not mean the heart has stopped or is about to. It means the heart is not pumping or filling as efficiently as it should, and in many cases this can be treated and even improved.
The confusing letters (HFrEF, HFpEF, and the newer HFimpEF) all describe one thing: the ejection fraction, or how much blood the main pumping chamber squeezes out with each beat.
Cardiologists separate these types because the underlying problem and the best treatment differ. The same label points the whole team toward the right medicines.
HFimpEF (improved ejection fraction) is the hopeful category. It describes people whose heart function has recovered, and the key lesson is that the medicines usually need to continue.
A new international consensus, the Second Universal Definition of Heart Failure published in June 2026, reframes heart failure as a condition that can change over time, with more focus on catching it early.

You have been told you have heart failure, and within the same conversation you have heard HFrEF, HFpEF, and perhaps HFimpEF. It sounds like alphabet soup, and it arrives at exactly the moment you are least equipped to decode it. The good news is that these terms are far less frightening once you understand what they are actually measuring, and why your cardiologist cares about the difference.

This article breaks the language down into plain English: what heart failure really means, what those letters stand for, why the distinction matters for your treatment, and what a major new international definition, published in June 2026, changes for patients.

Start With What Heart Failure Actually Means

The name is one of the cruellest in medicine. “Failure” suggests something has stopped, or is about to. That is not what it means. Heart failure is a clinical syndrome in which the heart cannot pump or fill with blood as efficiently as the body needs, usually producing symptoms such as breathlessness, fatigue, and swelling in the legs and ankles.

Crucially, it is not a single disease and it is not a death sentence. It is a description of how the heart is performing, and modern treatment can stabilise it, ease symptoms, and in a meaningful number of people improve the heart’s function substantially. To understand the categories, you first need to understand one number.

The Number Behind the Letters: Ejection Fraction

Every time the heart’s main pumping chamber, the left ventricle, contracts, it squeezes a percentage of the blood inside it out to the body. That percentage is the ejection fraction, usually shortened to EF. It is measured most often on an echocardiogram, the heart ultrasound.

A normal left ventricle does not empty completely. A healthy EF sits somewhere around 55% to 70%. So an EF of 60% is normal, not a sign that 40% is being left behind in a worrying way. This is the single most misread number in a cardiology report, so it is worth pausing on: a lower EF means the pump is weaker, but the EF is only one part of the picture, and it is not the whole story of how you will feel or fare.

The Three Main Types, Explained

Heart failure is grouped by ejection fraction because that number, more than almost anything else, tells the cardiologist what kind of problem they are dealing with and which treatments are likely to help. Here are the categories you are most likely to hear.

HFrEF: heart failure with reduced ejection fraction

This is the “weak pump” type. The EF is reduced, conventionally 40% or below, meaning the left ventricle is not contracting forcefully enough. The heart muscle has usually been damaged or weakened, and the squeeze is impaired. HFrEF is the type with the largest body of evidence behind its treatment, and, importantly, the type where the right combination of medicines can make the biggest difference.

HFpEF: heart failure with preserved ejection fraction

Here the EF is preserved, conventionally 50% or above, so the pump looks normal on paper. The problem is not the squeeze but the relaxation and filling. A stiff left ventricle cannot relax properly between beats, so it fills poorly and pressure backs up, producing the same symptoms of breathlessness and swelling. HFpEF is more common in older adults, in women, and in people with long-standing high blood pressure, diabetes, or obesity. For years it was the harder type to treat, though that has changed recently.

HFimpEF: heart failure with improved ejection fraction

This is the newest and most hopeful category. It describes someone who started with a reduced EF (40% or below) and, with treatment, has seen it recover to above 40%. Their heart has improved. The vital message attached to this label, and the reason cardiologists coined it rather than simply calling the person “better,” is that the improvement is usually because of the medicines, not instead of them. Stopping treatment because the numbers look good is one of the most common ways people relapse.

You may also hear HFmrEF, heart failure with mildly reduced ejection fraction, describing the middle band where EF sits between 41% and 49%. Think of it as the territory between the reduced and preserved categories, treated with a foot in both camps.

HFrEF: reduced

The pump is weak. Ejection fraction 40% or below. The muscle is not squeezing hard enough. Strong evidence exists for treatment that helps the heart recover.

HFpEF: preserved

The pump looks normal (EF 50% or above) but the ventricle is stiff and fills poorly. More common with age, in women, and with high blood pressure or diabetes.

HFimpEF: improved

Started reduced, now recovered above 40%. The good-news category, with one rule: the medicines that produced the recovery usually need to continue.

Why Cardiologists Bother Splitting Hairs

It is a fair question. If the symptoms are similar, why label the types at all? The answer is that the underlying mechanics are genuinely different, and so is the treatment that works. A medicine proven to save lives in a weak, reduced-EF heart may do little for a stiff, preserved-EF heart, and vice versa. The category is not bureaucratic tidiness. It is the shorthand that points your whole care team toward the treatments most likely to help you, and away from ones that will not.

Getting the category right also shapes what your cardiologist watches over time, from your BNP blood test to repeat scans that track whether your EF is holding steady, worsening, or improving.

The table below sets the three types side by side. It is a map, not a diagnosis, and your own cardiologist remains the person who reads it onto your particular heart.

Feature	HFrEF (reduced)	HFpEF (preserved)	HFimpEF (improved)
Ejection fraction	40% or below	50% or above	Was 40% or below, now above 40%
Core problem	A weak squeeze	A stiff chamber that fills poorly	A previously weak heart that has recovered
More common in	People with prior muscle damage or a weakened heart	Older adults, women, and people with high blood pressure or diabetes	People treated early and effectively for HFrEF
Treatment focus	The four pillars of medicine, built up together	Treating the drivers, plus SGLT2 inhibitors	Continuing the medicines that produced the recovery
Outlook message	Strong evidence that treatment helps	Improving fast as new evidence arrives	The hopeful category, if treatment continues

The label is not there to frighten you. It is there to make sure the right medicine reaches the right heart.

What Causes Each Type

The causes overlap, but they cluster differently across the categories, and identifying the cause is often as important as measuring the EF.

Reduced-EF heart failure most often follows damage to the heart muscle: a previous heart attack that has left a weakened area, longstanding uncontrolled blood pressure, disease of the heart muscle itself (the cardiomyopathies), heart rhythm problems such as atrial fibrillation, valve disease, or, in some people, alcohol and certain toxins.

Preserved-EF heart failure tends to grow out of years of a heart working against stiffening and pressure: chronic high blood pressure, diabetes, obesity, obstructive sleep apnoea, and ageing itself. Less commonly, an infiltrative condition such as cardiac amyloidosis stiffens the muscle, which matters because some of these causes now have specific treatments.

Improved-EF heart failure, by definition, starts as the reduced type and gets better, usually because the cause was treatable and the treatment worked. That is precisely why the medicines are rarely a temporary measure.

How Each Type Is Treated

This is where the categories earn their keep. The following is a general map, not a prescription. The right combination, and every dose, is individual, and only your own cardiologist can advise what is right for you.

For reduced-EF heart failure, the modern approach uses four classes of medicine together, often called the four pillars or quadruple therapy. In broad terms these are a medicine that relaxes and protects the blood vessels and heart (an ACE inhibitor, an ARB, or the combination agent Entresto), a beta-blocker, a mineralocorticoid receptor antagonist such as spironolactone, and an SGLT2 inhibitor. Used together and built up carefully, this combination has transformed outcomes over the past decade.

For preserved-EF heart failure, the picture has brightened considerably. SGLT2 inhibitors now have good evidence here too, which was not the case a few years ago. Beyond that, the priority is treating the drivers: controlling blood pressure and diabetes, managing weight, addressing sleep apnoea, and using diuretics to clear the fluid that causes congestion and breathlessness. Treating the specific cause, where there is one, matters more in this group than in any other.

For improved-EF heart failure, the treatment is, in most cases, to keep going. Trials have shown that stopping the medicines once the heart has recovered often allows the weakness to return. The recovery is best understood as the treatment succeeding, not as the illness disappearing, and the safest path is to maintain the therapy under your cardiologist’s guidance. Never stop a heart failure medicine without speaking to them first.

What the New 2026 Definition Changes

In June 2026, the world’s leading cardiovascular bodies, including the American Heart Association, the American College of Cardiology, the European Society of Cardiology, and the World Heart Federation, published the Second Universal Definition of Heart Failure, simultaneously in the journals JACC, Circulation, the European Heart Journal, and Global Heart. The American Heart Association has also released a plain-language summary for patients. It updates the first such definition from 2021, and although the document is written for clinicians, several of its changes matter to patients.

64 million
adults worldwide are estimated to live with heart failure, a number driven up by ageing populations and rising rates of high blood pressure, diabetes, and obesity.
American Heart Association, June 2026

First, it moves away from rigid cut-off numbers for ejection fraction and acknowledges that a normal EF differs by sex, age, and ethnicity, while keeping the familiar reduced, preserved, and improved categories as practical guides. Second, it puts far greater emphasis on catching heart failure early, before symptoms appear, so that prevention and treatment can start sooner. Third, and perhaps most reassuringly, it formally describes heart failure as a dynamic condition that can improve, go into remission, or progress, rather than a fixed, one-way diagnosis. The document is intended to be the foundation for the next major heart failure guideline, expected in 2027.

For a patient, the takeaway is encouraging: the field increasingly sees heart failure not as a static verdict but as a condition to be caught early, categorised accurately, and, in many people, improved.

Questions Worth Asking at Your Next Appointment

Which type of heart failure do I have, and what does that mean for my treatment?
What is my ejection fraction, and has it changed since my last echocardiogram?
Am I on the right combination of medicines for my specific type?
Are there conditions contributing to my heart failure, such as blood pressure, diabetes, or weight, that we should be managing more closely?
What symptoms should prompt me to contact the team between appointments?

Heart Matters Resource

When in Doubt, Get Checked Out

New breathlessness, unusual tiredness, or swelling in the legs are worth having assessed early. Heart failure is far more treatable when it is picked up sooner rather than later.

Read: When in Doubt, Get Checked Out →

Conclusion

The terminology around heart failure sounds far more alarming than the reality for most people. HFrEF, HFpEF, and HFimpEF are simply three ways of describing how well the heart’s main chamber is pumping and filling, and each points toward a different and increasingly effective set of treatments. The letters are a tool for getting you the right care, not a measure of how worried you should be.

If you have been given one of these labels, the most useful thing you can do is understand which type you have, take the medicines as prescribed even if you feel well, and keep the conversation with your cardiologist going. Heart failure is more treatable today than at any point in medical history, and, as the newest category reminds us, it can genuinely improve.

SCAD: Spontaneous Coronary Artery Dissection: What It Is and What to Expect

July 7, 2026

SCAD is a heart attack caused by a tear in the artery wall, not cholesterol. It mostly affects healthy women in their 40s and 50s, and the recovery outlook for most people is genuinely positive.

How to Measure Your Blood Pressure at Home

July 5, 2026

High blood pressure rarely causes symptoms, which is why measuring it regularly matters. This guide covers how to choose the right monitor and how to get accurate readings at home.

Conditions

Clot-Busting Drugs: When a Heart Attack Is Hours From Help

Pericarditis: Chest Pain That’s Worse Lying Down

When Blood Pressure Won’t Come Down: What Happens Next

The Hair Loss Question

Aortic Dissection: The Chest Pain That Cannot Wait

Cardiac Amyloidosis: The Stiff Heart Condition That’s Now Treatable

Demystifying Heart Failure: HFrEF, HFpEF and HFimpEF Explained

SCAD: Spontaneous Coronary Artery Dissection: What It Is and What to Expect

How to Measure Your Blood Pressure at Home

AI in Cardiology: What It Means for Your Heart, and What It Cannot Do

A High Calcium Score: What Does It Really Mean?

Aortic Stenosis: When the Heart’s Gateway Narrows

Patent Foramen Ovale (PFO): What the “Hole in the Heart” Finding Really Means

What is a Muscle Bridge?

White Coat Hypertension: When Your BP Spikes at the Doctor’s

Stroke and TIA Explained

Hypertrophic Cardiomyopathy: What HCM Actually Means

What Is Actually Happening in a Heart Attack

Two Ways to Open the Artery

Where the Clot-Busting Drugs Came From

How the Drug Works

The Two-Hour Rule

What We Check Before Giving It

Why the Journey Still Happens Afterwards

The Part That Matters Most

Conclusion

Related Reading

What the Pericardium Does

What It Feels Like

The pain has a recognisable pattern

Other symptoms

How the Diagnosis Is Made

What Causes It

Most often, no cause is ever found

COVID-19 and the vaccine question

The causes at a glance

How It Is Treated

When It Comes Back

The Complications That Matter

Conclusion

Related Reading

Minoxidil, the One People Are Sent to Ask About

The scalp solution

Low-dose tablets

Where the frightening warnings came from

Spironolactone, the Medicine Already on the List

What the evidence actually supports

The doses are not the same

Why this is a different conversation for men

Potassium, and the combinations that matter

The GLP-1 Question

When Hair Loss Is a Signal Rather Than a Complaint

Questions Patients Ask Me Most

When in Doubt, Get Checked Out

Conclusion

Related Reading

What Is an Aortic Dissection?

The Two Types, and Why the Difference Matters

What It Actually Feels Like

Why Blood Pressure Sits at the Centre of This

The Genetic Side, and When Family History Matters

Inherited connective tissue conditions

Bicuspid aortic valve

Familial aortic disease with no syndrome attached

Why It Is So Easily Missed

What You Can Actually Do

Conclusion

Related Reading

Start With What Heart Failure Actually Means

The Number Behind the Letters: Ejection Fraction

The Three Main Types, Explained

HFrEF: heart failure with reduced ejection fraction

HFpEF: heart failure with preserved ejection fraction

HFimpEF: heart failure with improved ejection fraction

Why Cardiologists Bother Splitting Hairs

What Causes Each Type

How Each Type Is Treated

What the New 2026 Definition Changes

When in Doubt, Get Checked Out